KW

Karen Wen, PhD

COO / Chief Strategy Officer

GenomeFrontier Therapeutics

Therapeutic Areas

GenomeFrontier Therapeutics Pipeline

DrugIndicationPhase
GF-CART01B cell malignanciesPreclinical
GF-CART02Multiple myelomaPreclinical
GF-CART03Solid tumorsPreclinical